The Advisory Board comprises senior executives and subject-matter experts with extensive experience across pharmaceuticals, biotechnology, medical technology, and global regulatory agencies. Their collective expertise will enhance Luminance Health’s ability to support clients – ranging from early-stage ventures to multinational enterprises and non-profit institutions – through each phase of the innovation lifecycle, from research and development to commercialization.

“The establishment of our Advisory Board represents a pivotal milestone for Luminance Health,” said Shayesteh Fürst-Ladani, Chief Executive Officer of Luminance Health. “Each member’s exceptional credentials and deep knowledge of the industry and its regulatory environment on a global perspective. will be instrumental in helping our clients to seize strategic opportunities, manage risk, and respond to the rapidly evolving demands of the healthcare ecosystem.”

Strategic Role and Value of the Advisory Board

The Advisory Board brings together a diverse group of experts with deep domain knowledge in regulatory science, clinical development, digital health, personalized medicine, and organizational strategy – empowering the company with sharper insights and more agile decision-making. Beyond expertise, these seasoned advisors unlock access to global networks, creating new avenues for strategic partnerships and cross-market growth. Their role in governance ensures heightened accountability and risk management, while their advice supports the ongoing development of the Luminance Health high-performance culture. Through collaborative thought leadership, the Advisory Board will also elevate Luminance Health’s profile as a bold and visionary voice in healthcare transformation.

Members of the Advisory Board

• Michael Doherty Mr Doherty is the Chair of Advisory Board and is an internationally recognized leader in regulatory affairs and precision medicines. Formerly Head of Product Development at Foundation Medicine and Global Head of Regulatory Affairs at Roche/Genentech, Mr. Doherty has successfully led multiple global approvals and introduced industry-defining genomic assays.

• Claus Bolte Former Chief Medical Officer at Swissmedic and current Vice President of the Board of Directors at University Hospital Basel. Dr. Bolte offers deep insight into clinical policy and regulatory strategy from his leadership roles and extensive network with global regulatory authorities.

• Marisa Papaluca A prominent authority in pharmaceutical regulatory science. Dr. Papaluca previously served as Senior Scientific Advisor at the European Medicines Agency and is currently an Honorary Professor at Imperial College London. Her work bridges regulatory innovation and public health policy.

• Thomas Metcalfe A seasoned executive in digital health and personalized healthcare. Mr. Metcalfe was a strategic leader at Roche and has held prior roles as CEO of Oncotest GmbH and Head of Roche’s Personalized Health CarePortfolio, where he spearheaded innovation across the diagnostic and therapeutic continuum.

• Franziskus Kath Dr. Kath has extensive experience in manufacturing, sourcing, quality assurance, and R&D formerly acting as Vice President Emerging Technologies and Product Quality Management at Jonson & Johnson. Dr. Kath is recognized for driving operational excellence and strategic growth across the life sciences industry.

As Luminance Health continues to expand its global presence and service offerings, the Advisory Board will serve as a key strategic partner in advancing client success, reinforcing organizational resilience, and sustaining long-term growth.

About Luminance Health

Luminance Health GmbH is a boutique consultancy that partners with life sciences and healthcare organizations to bring innovative products and services to market. Through tailored, cross-functional strategies encompassing development, regulatory compliance, and commercialization, Luminance Health empowers its clients to deliver sustainable impact and improve patient outcomes globally.